Vivek Subbiah: A clinical trial is not a last resort but can be a first option for people facing cancer.

Venkatraman Radhakrishnan: Reduction in chemo dose intensity by 25% and adding Rituximab improves survival in pediatric high-grade B Non-Hodgkins Lymphoma in resource-limited settings.

Kristina Jenei: This thread on drug shortages is better than most papers I’ve read about the subject.

Benoit Rousseau: This study pave the way for microbiome–immunotherapy interventions in GI cancers and vaccine strategies targeting intratumoral bacteria.

Tatiana Prowell: The first standardized definitions for efficacy endpoints in neoadjuvant breast cancer clinical trials (NeoSTEEP) are published in Journal of Clinical Oncology.

Jie Deng: Important takeaways to strengthen physician-scientists in the face of flat/declining NIH funding.

Jensa Morris: We found that implementing hospitalists allowed for shorter hospital stays and higher discharge rates to hospice in advanced cancer patients.

Lucia Masarova: Disease modification time in Polycythemia Vera is here!

Roelof van Ewijk: How should we move forward investigating new medicines in patients with refractory or recurrent osteosarcoma?

Steven O’Day: Today is World Cancer Research Day, which is a good day for me to share three things.